Sign up Australia
Proactive Investors - Run By Investors For Investors

Phylogica patents peptide technology to develop cell-penetrating drugs

Phylogica patents peptide technology to develop cell-penetrating drugs

Phylogica (ASX:PYC) has patented an improvement to its Phylomer peptide platform that will allow more efficient screening of its library of billions of naturally occurring peptides and identify those with the highest potential to target disease proteins inside the cells.

To develop a new generation of therapies, the peptides need to be able to deliver biologics drugs to cells where most targets are. To do this effectively, they need to penetrate natural cell membranes; target particular parts of the cell such as nuclei and ensure that drug cargos are not trapped in endosomes.

There is a significant requirement for technologies that improve the efficiency of the delivery of large therapeutic molecules such as proteins into cells as cell membranes can be major impediments.

Phylogica’s Endosomal Escape Trap enables the efficient identification of Phylomer cell-penetrating peptide-drug conjugates that not only deliver the therapeutic payload across the cell membrane, but also efficiently escape from the endosome so that the drug can have a therapeutic effect.

It is partnering with Genentech, a member of Roche Group (VTR:ROG); MedImmune- the biologics arm of AstraZeneca (LON:AZN); Pfizer and Janssen Biotech.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Register here to be notified of future PYC Company articles
View full PYC profile


October 06 2015
November 25 2014
November 07 2013

Related Articles

April 26 2016
Dr Stewart White, Collagen Solutions chief executive, told investors that the new partnership will expedite the roll-out of its medical grade collagen to customers in China.
March 02 2016
Lupuzor is not the only part of the Immupharma story and McCarthy plans also to raise the profile of the rest of the group's early stage pipeline in 2016.....
Cancer cell graphic
September 27 2016
Shares in Sareum have rocketed over 150% after it announced its cancer drug candidate has been licensed to ProNAi Therapeutics.

© Proactive Investors 2016

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.